晚期卵巢癌R0手术的个体化治疗

刘开江

中国实用妇科与产科杂志 ›› 2026, Vol. 42 ›› Issue (1) : 28-31.

PDF(1006 KB)
PDF(1006 KB)
中国实用妇科与产科杂志 ›› 2026, Vol. 42 ›› Issue (1) : 28-31. DOI: 10.19538/j.fk2026010107
专题笔谈

晚期卵巢癌R0手术的个体化治疗

作者信息 +

Individualized treatment for R0 surgery in advanced ovarian cancer

Author information +
文章历史 +

摘要

对于晚期卵巢癌肿瘤细胞减灭术达到R0切除,是改善晚期卵巢癌患者预后的最关键因素。手术能否达到R0主要取决3个因素:肿瘤扩散情况,患者身体状况和手术团队能力。R0切除是极其复杂并且需要多学科高度协作的系统工程,需要重视个体化治疗原则,包括选择合适的手术时机,合理的手术方式,足够的手术范围才能达到满意的肿瘤细胞减灭术。

Abstract

Achieving R0 resection during cytoreductive surgery for advanced ovarian cancer represents the most critical factor for improving patient prognosis. The success of R0 resection primarily depends on three factors: the extent of disease spread,the patient's overall condition,and the surgical team's expertise. R0 resection is an extremely complex systematic procedure and requires high degree of multidisciplinary collaboration. Emphasizing an individualized treatment approach—including selecting the optimal timing for surgery,the appropriate surgical technique,and the sufficient extent of resection—is essential to achieving satisfactory cytoreduction.

关键词

卵巢癌 / R0手术 / 个体化治疗

Key words

ovarian cancer / R0 surgery / individualized treatment

引用本文

导出引用
刘开江. 晚期卵巢癌R0手术的个体化治疗[J]. 中国实用妇科与产科杂志. 2026, 42(1): 28-31 https://doi.org/10.19538/j.fk2026010107
LIU Kai-jiang. Individualized treatment for R0 surgery in advanced ovarian cancer[J]. Chinese Journal of Practical Gynecology and Obstetrics. 2026, 42(1): 28-31 https://doi.org/10.19538/j.fk2026010107
中图分类号: R737.3   

参考文献

[1]
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1):17-48. DOI:10.3322/caac.21763.
[2]
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China,2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. DOI:10.1016/j.jncc.2024.01.006.
[3]
Caruso G, Weroha SJ, Cliby W. Ovarian cancer: a review[J]. JAMA, 2025, 334(14):1278-1291. DOI:10.1001/jama.2025.9495.
[4]
曹冬焱, 向阳. 卵巢癌手术质量控制[J]. 中国实用妇科与产科杂志, 2022, 38(1):29-32. DOI:10.19538/j.fk2022010108.
[5]
Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis[J]. Semin Surg Oncol, 1994, 10(1):12-20. DOI:10.1002/ssu.2980100105.
[6]
Reuss A, du Bois A, Harter P, et al. TRUST:Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7)[J]. Int J Gynecol Cancer, 2019, 29(8):1327-1331. DOI:10.1136/ijgc-2019-000682.
[7]
Melamed A, Rauh-Hain JA, Gockley AA, et al. Association between overall survival and the tendency for cancer programs to administer neoadjuvant chemotherapy for patients with advanced ovarian cancer[J]. JAMA Oncol, 2021, 7(12):1782-1790. DOI:10.1001/jamaoncol.2021.4252.
[8]
Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)[J]. Int J Gynecol Cancer, 2020, 30(11):1657-1664. DOI:10.1136/ijgc-2020-001640.
[9]
Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage Ⅲ/Ⅳ ovarian,tubal and peritoneal cancers in phase Ⅲ randomised trial[J]. Eur J Cancer, 2020, 130:114-125. DOI:10.1016/j.ejca.2020.02.020.
[10]
Jiang R, Feng Y, Chen Y, et al. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer:final overall survival analysis of the SOC-1 randomized phase 3 trial[J]. Nat Med, 2024, 30(8):2181-2188. DOI:10.1038/s41591-024-02981-0.
[11]
Jochum F, Dumas É, Gougis P, et al. Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stageⅣovarian cancer:a nationwide population-based target trial emulation[J]. Am J Obstet Gynecol, 2025, 232(2):194.e1-194.e11. DOI:10.1016/j.ajog.2024.07.044.
[12]
朱连成, 林蓓. 新辅助化疗对卵巢癌肿瘤细胞减灭术手术结局的影响[J]. 中国实用妇科与产科杂志, 2023, 39(7):706-711. DOI:10.19538/j.fk2023070108.
[13]
Ji Hyun Kim, Myong Cheol Lim, Sang-Yoon Park, et al. Survival outcomes of advanced ovarian cancer treated with neoadjuvant chemotherapy versus primary cytoreductive surgery using a quality-assured decision-making approach[J]. J Clin Oncol, 2025, 43:5577-557. DOI:10.1200/JCO.2025.43.16_suppl.5577.
[14]
Miceli V, Gennarini M, Tomao F, et al. Imaging of Peritoneal Carcinomatosis in Advanced Ovarian Cancer: CT,MRI,Radiomic Features and Resectability Criteria[J]. Cancers (Basel), 2023, 15(24):5827. DOI:10.3390/cancers15245827.
[15]
Tsili AC, Alexiou G, Tzoumpa M, et al. Imaging of peritoneal metastases in ovarian cancer using MDCT,MRI,and FDG PET/CT: a systematic review and meta-analysis[J]. Cancers (Basel), 2024, 16(8):1467. DOI:10.3390/cancers16081467.
[16]
Rauh-Hain JA, Melamed A, Pareja R, et al. Laparoscopic cytoreduction after neoadjuvant chemotherapy in high-grade epithelial ovarian cancer: a lance randomized clinical trial[J]. JAMA Netw Open, 2024, 7(11):e2446325. DOI:10.1001/jamanetworkopen.2024.46325.
[17]
Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed,advanced ovarian cancer: ASCO guideline update[J]. J Clin Oncol, 2025, 43(7):868-891. DOI:10.1200/JCO-24-02589.
[18]
Tsunoda AT, Dos Reis R, Moretti-Marques R, et al. Surgery in ovarian cancer-Brazilian Society of Surgical Oncology consensus[J]. J Surg Oncol, 2025, 132(4):640-653. DOI:10.1002/jso.70055.
[19]
陈春林, 李维丽. 重视临床应用解剖学研究——对妇产科手术进行系统分区[J]. 中国实用妇科与产科杂志, 2025, 41(1):26-30. DOI:10.19538/j.fk2025010107.
[20]
狄文, 张楠. 卵巢恶性肿瘤诊疗观念的思考与挑战[J]. 中国实用妇科与产科杂志, 2024, 40(11):1057-1060. DOI:10.19538/j.fk2024110101.

脚注

利益冲突 作者声明不存在利益冲突

基金

国家自然科学基金(82371652)
上海交通大学“医工交叉”重点项目(YG2024ZD06)

PDF(1006 KB)

Accesses

Citation

Detail

段落导航
相关文章

/